TAXUS ATLAS LONG LESION: A multi-center, single-arm study of the TAXUS Liberte-SR stent for the treatment of patients with long de novo coronary artery lesions.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms ATLAS-Long-Lesion
Sponsors Boston Scientific Corporation

22 Sep 2009 Three-year results were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, according to a Boston Scientific media release.
05 Feb 2009 Clinical data from this trial form part of the pre-marketing approval application submitted to the FDA for Taxus Liberte Long paclitaxel-eluting coronary stent system, according to a media release from Boston Scientific.
01 Dec 2008 Primary endpoint 'In stent restenosis' has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com